Viking Therapeutics (VKTX) Trading 0.2% Higher

Viking Therapeutics Inc (NASDAQ:VKTX) shares traded up 0.2% during trading on Monday . The company traded as high as $6.37 and last traded at $6.08. 3,019,147 shares were traded during mid-day trading, an increase of 113% from the average session volume of 1,420,298 shares. The stock had previously closed at $6.07.

A number of research analysts recently commented on the stock. Maxim Group reiterated a “buy” rating and issued a $8.00 price target on shares of Viking Therapeutics in a research note on Friday. Roth Capital set a $6.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 29th. ValuEngine lowered shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Viking Therapeutics in a research note on Friday, November 10th.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.03). research analysts predict that Viking Therapeutics Inc will post -0.86 EPS for the current year.

Several large investors have recently made changes to their positions in VKTX. Citadel Advisors LLC acquired a new position in shares of Viking Therapeutics during the 3rd quarter worth approximately $108,000. Virtu KCG Holdings LLC acquired a new position in shares of Viking Therapeutics during the 2nd quarter worth approximately $124,000. Creative Planning grew its position in shares of Viking Therapeutics by 600.0% during the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 60,000 shares in the last quarter. Sabby Management LLC acquired a new position in shares of Viking Therapeutics during the 2nd quarter worth approximately $525,000. Finally, Sphera Funds Management LTD. acquired a new position in shares of Viking Therapeutics during the 3rd quarter worth approximately $554,000. Hedge funds and other institutional investors own 5.86% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/02/05/viking-therapeutics-vktx-trading-0-2-higher.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit